Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations.

ABSTRACT:

Introduction

In this study, we sought to further characterize ROS1 protein expression in solid tumors with the complete spectrum of ROS1 genomic alterations.

Methods

ROS1 immunohistochemistry (IHC) was performed using the ROS1 (SP384) class I assay per manufacturer's instructions on a variety of solid tumors (n = 32) with known ROS1 genomic alterations. Genomic alterations included fusions (n = 17), gene amplifications (n = 10), and short-variant mutations (n = 11).

Results

Of the 32 cases with ROS1 IHC results, 100% (11 of 11) with canonical ROS1 fusions were positive for ROS1 IHC. Among noncanonical ROS1 fusions, only two (of five) cases with SQSTM1-ROS1 and RDX-ROS1 fusions were positive for ROS1 IHC whereas PTPRK-

SUBMITTER: Huang RSP 

PROVIDER: S-EPMC8474213 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature